267 related articles for article (PubMed ID: 37070982)
1. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
[TBL] [Abstract][Full Text] [Related]
2. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
[TBL] [Abstract][Full Text] [Related]
3. Applications of coxsackievirus A21 in oncology.
Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
Relph K; Annels N; Smith C; Kostalas M; Pandha H
Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
[TBL] [Abstract][Full Text] [Related]
5. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
Skelding KA; Barry RD; Shafren DR
Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
[TBL] [Abstract][Full Text] [Related]
6. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
Burnett WJ; Burnett DM; Parkman G; Ramstead A; Contreras N; Gravley W; Holmen SL; Williams MA; VanBrocklin MW
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503272
[TBL] [Abstract][Full Text] [Related]
7. Potent oncolytic activity of human enteroviruses against human prostate cancer.
Berry LJ; Au GG; Barry RD; Shafren DR
Prostate; 2008 May; 68(6):577-87. PubMed ID: 18288643
[TBL] [Abstract][Full Text] [Related]
8. Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18.
Au GG; Beagley LG; Haley ES; Barry RD; Shafren DR
Virol J; 2011 Jan; 8():22. PubMed ID: 21241513
[TBL] [Abstract][Full Text] [Related]
9. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
Au GG; Lincz LF; Enno A; Shafren DR
Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
[TBL] [Abstract][Full Text] [Related]
11. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.
Hadac EM; Kelly EJ; Russell SJ
Mol Ther; 2011 Jun; 19(6):1041-7. PubMed ID: 21505425
[TBL] [Abstract][Full Text] [Related]
12. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
Marino N; Illingworth S; Kodialbail P; Patel A; Calderon H; Lear R; Fisher KD; Champion BR; Brown ACN
PLoS One; 2017; 12(5):e0177810. PubMed ID: 28542292
[TBL] [Abstract][Full Text] [Related]
13. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H
Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024
[TBL] [Abstract][Full Text] [Related]
14. Binding of Coxsackievirus A21 procapsids to immobilized glutathione depends on cell culture conditions during infection.
Swartz AR; Shieh Y; Gulasarian A; Olson JW; Rustandi RR
Virology; 2022 Aug; 573():167-175. PubMed ID: 35834888
[TBL] [Abstract][Full Text] [Related]
15. The Effects of Mesenchymal Stem Cells Loaded with Oncolytic Coxsackievirus A21 on Mouse Models of Colorectal Cancer.
Karbalaee R; Mehdizadeh S; Ghaleh HEG; Izadi M; Kondori BJ; Dorostkar R; Hosseini SM
Curr Cancer Drug Targets; 2024 Jan; ():. PubMed ID: 38310465
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA.
Elsedawy NB; Nace RA; Russell SJ; Schulze AJ
Mol Ther Oncolytics; 2020 Jun; 17():484-495. PubMed ID: 32529026
[TBL] [Abstract][Full Text] [Related]
17. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western.
Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW
Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264
[TBL] [Abstract][Full Text] [Related]
18. [Oncolytic coxsackievirus therapy as an immunostimulator].
Miyamoto S; Sagara M; Kohara H; Tani K
Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the stability and intratumoral delivery of foreign transgenes encoded by an oncolytic Foamy Virus vector.
Budzik KM; Nace RA; Ikeda Y; Russell SJ
Cancer Gene Ther; 2022 Aug; 29(8-9):1240-1251. PubMed ID: 35145270
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer.
Annels NE; Mansfield D; Arif M; Ballesteros-Merino C; Simpson GR; Denyer M; Sandhu SS; Melcher AA; Harrington KJ; Davies B; Au G; Grose M; Bagwan I; Fox B; Vile R; Mostafid H; Shafren D; Pandha HS
Clin Cancer Res; 2019 Oct; 25(19):5818-5831. PubMed ID: 31273010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
